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The variance in glycemic control between
different childhood diabetes centers is
not fully understood. Although the In-
ternational Society for Pediatric and Ad-
olescent Diabetes guidelines from 2014
recommended center sizes of more
than 150 patients (1), it has not been
thoroughly investigated whether glyce-
mic control is associated with center size
(2–4). We have data from more than
500 childhood diabetes centers from
seven different countries and thereby
a unique opportunity to elaborate fur-
ther on this association. Therefore, this
study aims to investigate the relationship
between center size andglycemic control
in children with type 1 diabetes (T1D).
Patient data have been described
previously (5). Briefly, the population
comprised children with T1D in the age-
group ,18 years and diabetes duration
of .3 months from seven high-income
countries during 2013–2014: Austria,
Denmark, England, Germany, Norway,
Sweden, and Wales. Data were anonym-
ized and obtained from five national
registries/audits on children with T1D
(Austria and Germany use the same
electronic health record and England
and Wales have a common National
Pediatric Diabetes Audit, while Denmark,
Norway, and Sweden have national reg-
istries). Mean HbA1c was compared be-
tween groups after adjusting for sex, age
(,6 years, 6 to ,12 years, and 12–18
years), duration of diabetes (,2 years,
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2 to,5 years, and$5 years), andminority
status (yes/no) (HbA1c adj) before and
after stratifying for treatment modality
(insulin injection/pump). Center size was
defined as the number of patients with
diabetes reported to be cared for in
a center. Center size groupings were
1) ,20, 2) 20 to ,50, 3) 50 to ,100, 4)
100 to ,200, and 5) $200 patients.
In total 54,494 children (48% females)
with T1D across 504 centers in seven
countrieswere included in the study. The
number of centers per country varied
between 14 (Wales) and 219 (Germany).
Mean (SD) for age was 12.5 (3.9) years,
mean age at T1D onset was 7.5 (4.0)
years, and mean T1D duration was 5.0
(3.7) years. A total of 21% of patients had
minority status, which varied between
5% (Wales) and 28% (Austria). A total of
38.1% of patients were on pump treat-
ment, and thepercentage variedbetween
25% (England) and 69% (Denmark). Na-
tional coverage of T1D patients was.95%
in all countries, apart fromAustria, which
had ;80% data coverage. Included pa-
tients had 100% data coverage for all
variables, sex, age, diabetes duration,
minority status, and HbA1c. Data on
treatment modality were not available
for 2,428 patients (4.5%); of these, 2,130
were from England and 154 were from
Sweden.
A total of 23.2% of centers had ,50
patients (small centers) with T1D, which
represented 4.9% of the total patient
population. Most children (45.6%) were
cared for in diabetes centers with a
center size between 100 and 200 pa-
tients. A total of 30.2% of children were
cared for in centers with.200 patients,
representing 12.3% of all centers. The
distribution of small and large centers in
the seven countries varied. England and
Sweden had few small centers (,12%),
while Austria, Germany, and Norway
had a higher percentage of small cen-
ters (.34%). HbA1c adj was significantly
higher in the centers with ,50 patients
comparedwith larger centers (P,0.001),
while there was no difference in HbA1c adj
with increasing center size above 50 pa-
tients (Fig. 1). Stratification for treatment
modality (insulin injection/pump) re-
vealed that HbA1c adj was significantly
higher in centers with,50 patients com-
pared with centers with.50 patients, in
both pen users (P , 0.001) and pump
users (P , 0.01). The influence of center
size was more pronounced in pen users,
and pen users had higher HbA1c adj than
pump users for all center sizes (P, 0.02)
(Fig. 1).
We conclude that the percentage of
small and larger centers differed be-
tween countries, but in total the small
centers (,50 patients) comprised 23.2%
of all diabetes centers in the seven
countries. In all countries combined,
childhood diabetes centers with ,50
patients had higher HbA1c. This indicates
that, where geographically possible, it
may be beneficial to reduce the number
of small centers and combine them into
larger entities.As small centersdidbetter
on pump than pen, small remote centers
may benefit from encouraging pump use.
Diabetes centerswith.50patientsman-
aged equally well; therefore, centralizing
to very-high-volume diabetes centers
may not necessarily be an advantage.
Future research should focus on identi-
fying reasons leading to differences in
glycemic control in T1D patients cared
for in small and large centers, e.g., the
lack or presence of an updated multidis-
ciplinary diabetes team.
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